Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Tempus AI — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while Tempus AI trades at $67.03 (market cap $12.39B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.5× Tempus AI's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| GEHC | TEM | |
|---|---|---|
Market Cap | $31.07B | $12.39B |
Volume | 3,443,020 | 4,141,569 |
Sector | Health | Broad Market / Factor |
52-Week High | $88.16 | $92.45 |
52-Week Low | $59.48 | $41.55 |
Enterprise Value | $39.53B | $13.01B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 23 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Tempus AI (TEM) trades at $68.22, up 0.34% with a bullish technical signal despite negative profitability. The stock shows strong analyst support with 64% buy ratings and a $72.60 consensus target. Recent FDA clearance for ECG-MR AI product and ESMO conference presentations highlight ongoing innovation, while Q2 2026 earnings beat expectations with 22% revenue growth. Cash flow remains positive primarily from financing activities.
While TEM demonstrates strong revenue growth and product innovation, significant risks persist including negative net margins (-17.77%) and substantial insider selling. The stock's high P/B ratio of 27.84 suggests premium valuation despite unprofitability. Near-term catalysts include Q3 earnings and ESMO presentations, but investors should weigh growth potential against persistent losses and competitive pressures in AI healthcare.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
